Western States is a privately held biopharmaceutical company developing novel therapies that selectively modulate adaptive immunity to treat inflammatory diseases.

Currently valued over $16B, the global autoimmune market still does not have therapies that adequately address either the efficacy or safety needs of patients with diseases like Rheumatoid Arthritis. Competitors like Enbrel, Humira, and Remicade work well in less than 25% of patients and expose them to serious infections and malignancies resulting in FDA warnings. This efficacy diminishes over time leaving patients with few options.

Western States has discovered a way to block the destructive effects of these diseases without affecting the immune system's natural ability to fight disease. This breakthrough approach promises to offer physicians and patients improved options for fighting the disability of many inflammatory diseases.

The company founders have deep leadership experience in discovering, developing, and commercializing therapies in autoimmune disease, and are currently advancing the program in preparation for human clinical studies.